



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Gessica Filocamo et al.	
Serial No.:	10/586,701	Case No.: ITR0064YP
Filed:	July 20, 2006	
For:	INHIBITORS OF MAMMALIAN HDAC 11 USEFUL FOR TREATING HDAC 11 MEDIATED DISORDERS	

Art Unit:
To be assigned

Examiner:
To be assigned

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

SUBMISSION OF SEQUENCE STATEMENT

Sir:


In compliance with 37 C.F.R. 1.821(f) of the Rules of Practice In Patent Cases: Application Disclosures Containing Nucleotide And/Or Amino Acid Sequences, the following statement is being submitted with the computer readable form of the Sequence Listing.

I hereby start that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. 1.821(c) and (e), respectively, are the same.

Applicants respectfully contend that the sequences listed in the Sequence Listing were included in the application as originally filed and that the Sequence Listing therefore does not add new matter to the application.

The enclosed diskette contains the Sequence Listing for Case No. ITR0064YP.

Respectfully submitted,


By: 

Vineet Kohli
Registration No. 37,003
Attorney for Applicants

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450, ON THE DATE APPEARING BELOW.

MERCK & CO., INC

MAILED BY:  DATE: 8-13-08

Date: August 13, 2008

Merck & Co., Inc.
P.O. Box 2000 - RY 60-30
Rahway, New Jersey 07065-0907
Telephone No. (732) 594-3889